drugset / Trial / NCT05669144

Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery

NCT05669144

Phase 1/2 Unknown 20 enrolled Tehran University of Medical Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Heart failure (HF) and acute myocardial infarction that often follows are among the main causes of disability and death worldwide. As such, new treatments and biological drugs are needed to protect the heart against the harmful effects of ischemia and also reperfusion injury (IRI), preserve cardiac function, reduce the zone of myocardial infarction (MI), and improve patient outcomes. In this regard, it has been shown that mitochondrial dysfunction has a key role in the pathogenesis of heart ischemia, cardiomyopathy, and reperfusion injury. in this study which includes 4 groups of intervention, we try to minimize the damage by transplantation of mitochondria and administration of MSC-derived exosomes. MSC-derived exosomes limit inflammatory damage while fresh autologous exosomes limit oxidative stress.

Timeline

Start
2022-04-20
Primary completion
2023-09-20
Completion
2024-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject MSC-derived exosomes Other / unclassified 100 ug Other
Subject mitochondria Unknown 1e+07 unknown Other